Diagnosing amyloidosis typically requires a combination of blood and urine tests, tissue biopsy, and specialized imaging, with the specific pathway depending on which type of amyloidosis is suspected. The process is notoriously slow: the median time from earliest symptoms to a confirmed diagnosis of AL amyloidosis (the most common systemic type) ranges from about 3 to 21 months, largely because symptoms overlap with many other conditions.
Why Amyloidosis Is Hard to Catch Early
Amyloidosis causes misfolded proteins to accumulate in organs, and those deposits can affect the heart, kidneys, nerves, liver, or digestive tract. Because the symptoms mimic so many other diseases (shortness of breath, swelling, fatigue, numbness in the hands and feet), patients often cycle through multiple specialists before anyone considers amyloidosis. The condition is rare enough that it simply isn’t on most doctors’ radar during a first visit for heart failure or unexplained kidney problems.
A few physical signs, when present, point strongly toward amyloidosis. About 10% of people with AL cardiac amyloidosis develop macroglossia, a noticeable enlargement of the tongue or subtle tooth indentations along its edges. Periorbital bruising, purplish discoloration around the eyes that appears without injury, is another hallmark. When either of these shows up alongside heart failure symptoms, the combination is considered essentially diagnostic for AL amyloidosis. The problem is that most patients never develop these visible clues.
Blood and Urine Screening
The first round of testing is minimally invasive: blood draws and a urine sample. For AL amyloidosis, which is caused by abnormal antibody fragments called light chains, the key screening test is the serum free light chain assay. This measures two types of light chains (kappa and lambda) and calculates their ratio. Normal ranges are 0.33 to 1.94 mg/dL for kappa, 0.57 to 2.63 mg/dL for lambda, and a kappa-to-lambda ratio between 0.26 and 1.65. A ratio outside that range is abnormal in about 88% of AL amyloidosis patients.
Doctors also order serum protein electrophoresis with immunofixation, which separates blood proteins to look for an abnormal spike suggesting a clonal plasma cell disorder. Urine testing follows the same logic. A 24-hour or early morning urine sample is analyzed with urine protein electrophoresis and immunofixation to look for Bence Jones proteins, which are light chains that spill into the urine. Standard urine dipsticks detect albumin, not these light chains, so a normal dipstick result does not rule out the problem. Immunofixation electrophoresis is actually more sensitive than the free light chain blood test for detecting these proteins in amyloidosis specifically.
Tissue Biopsy: The Definitive Test
No blood test alone confirms amyloidosis. The gold standard is a tissue biopsy stained with a dye called Congo red. Under a polarizing microscope, amyloid deposits stained with Congo red produce a characteristic color shift, historically described as “apple-green birefringence.” More recent guidelines from the International Society of Amyloidosis recognize that green, orange, or yellow birefringence all count as positive findings.
The least invasive biopsy option is abdominal fat pad aspiration, where a needle draws a small sample of fat from just below the skin of the abdomen. The procedure is quick, can be done in an office, and carries very little risk. Its sensitivity varies widely, though, from as low as 14% in some studies to over 90% in others, depending on the center’s technique and the type of amyloidosis involved. Because of its simplicity, fat pad aspiration is usually tried first.
If the fat pad sample comes back negative but suspicion remains high, the next step is a biopsy of the affected organ itself. For suspected cardiac amyloidosis, that means an endomyocardial biopsy, where a catheter is guided into the heart to collect a tiny tissue sample. This is the most reliable method for confirming cardiac involvement but carries a small risk of complications and requires specialized expertise. Biopsies of the kidney, liver, or nerve may be used when those organs appear to be the primary targets.
Typing the Amyloid
Confirming the presence of amyloid is only half the job. Identifying which protein is forming the deposits is critical because the two most common systemic types, AL and ATTR, require completely different treatments. Typing is done on the biopsy tissue itself, typically through mass spectrometry or immunohistochemistry, which identify the exact protein in the deposits.
For ATTR amyloidosis (caused by the transthyretin protein), genetic testing determines whether the condition is hereditary or age-related. A simple blood test sequences the TTR gene. The most common hereditary mutation worldwide is Val50Met (historically called Val30Met), which is a founder variant in Portugal, Sweden, and Japan and tends to cause nerve damage. The Val142Ile variant (historically Val122I) is present in 3% to 4% of African Americans and primarily causes late-onset heart disease. More than 5% of the population in some parts of West Africa carries this variant. If no mutation is found, the diagnosis is wild-type ATTR, an age-related form most common in men over 70.
Genetic testing is also recommended for apparently healthy adult relatives of someone with a confirmed hereditary mutation, because early identification allows earlier treatment and monitoring before organ damage progresses.
Imaging for Cardiac Amyloidosis
When the heart is suspected to be involved, imaging plays a major role in both diagnosis and severity assessment. Echocardiography often provides the first clue: thickened heart walls with a distinctive “sparkling” or granular appearance, along with diastolic dysfunction, are classic findings.
A nuclear bone scan using a radioactive tracer called technetium pyrophosphate (PYP scan) has become a game-changer for diagnosing ATTR cardiac amyloidosis specifically. The tracer binds to transthyretin amyloid deposits in the heart, and uptake is graded on a four-point scale. Grade 0 means no visible cardiac uptake. Grade 1 shows mild uptake less intense than the surrounding bone. Grade 2 shows moderate uptake equal to or greater than bone. Grade 3 shows strong cardiac uptake with little or no bone signal visible. A grade 2 or 3 result, combined with the absence of a monoclonal protein in blood and urine tests (ruling out AL), can confirm ATTR cardiac amyloidosis without a heart biopsy. This non-invasive pathway has dramatically simplified diagnosis for many patients.
Cardiac MRI adds another layer of detail. When a contrast agent called gadolinium is injected, amyloid deposits cause distinctive enhancement patterns. In AL amyloidosis, the enhancement tends to appear as a ring just beneath the inner surface of the heart wall. In ATTR amyloidosis, it more often extends through the full thickness of the wall. About 93% of ATTR patients show this full-thickness pattern in at least one segment, compared to roughly 31% of AL patients. The absence of right ventricular enhancement can also help distinguish AL from ATTR, as about one-third of AL patients show no right-sided involvement.
Staging After Diagnosis
Once amyloidosis is confirmed and typed, doctors assess how much organ damage has already occurred. For AL amyloidosis, the most widely used system is the Mayo 2012 staging model, which assigns a stage (I through IV) based on three blood biomarkers: high-sensitivity troponin T (a marker of heart muscle injury), NT-proBNP (a marker of heart strain), and the difference between involved and uninvolved free light chains. The cutoff values are troponin T below 40 ng/L, NT-proBNP below 1,800 pg/mL, and a light chain difference below 180 mg/L. Each value above its threshold adds one point, and the total determines the stage. Higher stages indicate more advanced cardiac involvement and help guide treatment urgency.
A European modification of an earlier staging system uses slightly different thresholds, with troponin T below 50 ng/L and NT-proBNP below 332 ng/L, and further subdivides advanced disease using an NT-proBNP cutoff of 8,500 ng/L. Both systems serve the same purpose: quantifying heart damage to predict outcomes and tailor therapy intensity.
For ATTR amyloidosis, staging relies on NT-proBNP and estimated kidney function, though the specifics vary by center. Regardless of type, the staging process is what translates a diagnosis into a treatment plan.